• Company
• Interleukin inhibitors Cosentyx·Tremfya busy extending reim
• by Eo, Yun-Ho Jun 5, 2023 05:37am

• Opinion
• [Reporter’s View]Rise of adjuvant therapies amid concerns
• by Eo, Yun-Ho Jun 5, 2023 05:37am

• Policy
• The method of revaluation of wages that Godex has changed
• by Lee, Tak-Sun Jun 5, 2023 05:36am

• Company
• Forxiga will maintain its price for 10 months in KOR
• by Jung, Sae-Im Jun 2, 2023 05:38am

• Company
• BMS and Gilead compete tightly in HBV drug market in KOR
• by Nho, Byung Chul Jun 2, 2023 05:38am

• Company
• K-Pharma Bio ASCO launch table
• by Hwang, Jin-joon Jun 1, 2023 05:43am

• Company
• The share of the domestic bio-industry is around 1%
• by Hwang, Jin-joon Jun 1, 2023 05:42am

• Company
• ↓Sales of Nexavar and Lenvima &↑Sales of Cabometyx
• by Kim, Jin-Gu Jun 1, 2023 05:39am

• Company
• The only non-reimbursed Evrysdi struggle in the market
• by Jung, Sae-Im Jun 1, 2023 05:39am

• Company
• SK bioscience's coronavirus vaccine, approved in the UK
• by Kim, Jin-Gu Jun 1, 2023 05:39am